MedTrace Logo

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

Conditions

Interventions

DRUG

ALTA3263

Oral ALTA3263 tablets will be administered at a protocol-defined dose

DRUG

cetuximab

Cetuximab injection for IV use will be administered at a protocol-defined dose

Sponsors & Collaborators

  • Alterome Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Medical Director · Alterome Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2029-05-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06835569 on ClinicalTrials.gov